Target Name: WIPI2
NCBI ID: G26100
Review Report on WIPI2 Target / Biomarker Content of Review Report on WIPI2 Target / Biomarker
WIPI2
Other Name(s): WD repeat domain phosphoinositide-interacting protein 2 (isoform a) | WIPI2 variant 1 | WIPI49-like protein 2 | WIPI2_HUMAN | WIPI-2 | WD repeat domain phosphoinositide-interacting protein 2 (isoform d) | WD repeat domain phosphoinositide-interacting protein 2 | ATG18B | IDDSSA | Atg21 | WD repeat domain, phosphoinositide interacting 2 | WD repeat domain phosphoinositide-interacting protein 2 (isoform b) | WD repeat domain, phosphoinositide interacting 2, transcript variant 4 | WIPI2 variant 4 | WIPI2 variant 2 | CGI-50 | WD repeat domain, phosphoinositide interacting 2, transcript variant 2 | WD40 repeat protein interacting with phosphoinositides 2 | WD repeat domain, phosphoinositide interacting 2, transcript variant 1

WIPI2 as A Potential Drug Target and Biomarker for Diseases

WIPI2 (WD repeat domain phosphoinositide-interacting protein 2) is a protein that is expressed in various tissues and cells throughout the body. It plays a crucial role in the regulation of cell signaling pathways, including the Fc portion of integrins, which are involved in cell-cell and cell-matrix interactions. WIPI2 is a protein that has been identified as a potential drug target and may also be a biomarker for various diseases.

WIPI2 Structure and Function

WIPI2 is a 12kDa protein that contains a WD repeat domain, a N-terminal alpha-helix, and a C-terminal T-loop. The WD repeat domain is a known structural domain that is found in various proteins that are involved in protein- protein interactions, while the N-terminal alpha-helix and C-terminal T-loop provide stability and flexibility to the protein.

WIPI2 is involved in the regulation of several cellular processes, including cell signaling pathways, cytoskeletal organization, and cell adhesion. One of the well-documented functions of WIPI2 is its role in the regulation of integrins, which are proteins that are involved in cell- cell and cell-matrix interactions. Integrins are essential for many cellular processes, including cell adhesion, migration, and invasion.

WIPI2 has been shown to play a role in the regulation of integrin signaling by affecting the stability and activity of integrins. Studies have shown that WIPI2 can interact with several different integrins, including 伪4 (also known as CD73) and 伪6 (also known as CD72 ). These interactions are critical for the regulation of integrin signaling and the formation of integrin aggregates, which can have a negative impact on the stability and activity of integrins.

In addition to its role in integrin signaling, WIPI2 has also been shown to play a role in the regulation of cell signaling pathways. WIPI2 has been shown to interact with several different signaling proteins, including TGF-β1, FGF, and PDGF. These interactions are critical for the regulation of cell signaling pathways and the development of various diseases.

WIPI2 as a Potential Drug Target

WIPI2 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with the development of various diseases. One of the main reasons for the identification of WIPI2 as a potential drug target is its involvement in the regulation of integrin signaling, which is a key pathway in the regulation of cellular processes that are associated with the development of various diseases, such as cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its involvement in integrin signaling, WIPI2 has also been shown to play a role in the regulation of cell signaling pathways, which are also involved in the development of various diseases. For example, WIPI2 has also been shown to interact with TGF-β1 , a protein that is involved in the regulation of cell signaling pathways and the development of various diseases, including cancer.

WIPI2 has also been shown to interact with FGF, a protein that is involved in the regulation of cell signaling pathways and the development of various diseases, including cancer. Additionally, WIPI2 has been shown to interact with PDGF, a protein that is involved in the regulation of cell signaling pathways and the development of various diseases, including cancer.

WIPI2 as a Potential Biomarker

In addition to its potential as a drug target, WIPI2 has also been shown to be a potential biomarker for several diseases. One of the main reasons for the identification of WIPI2 as a potential biomarker is its involvement in the regulation of integrin signaling, which is a key pathway in the regulation of cellular processes that are associated with the development of various diseases, such as cancer, neurodegenerative diseases, and autoimmune diseases.

WIPI2 has been shown to interact with several different signaling proteins, including TGF-β1, FGF, and PDGF. These interactions are critical for the regulation of cell signaling pathways and the development of various diseases. Therefore, WIPI2 may be a useful biomarker for the diagnosis and treatment of diseases associated with altered signaling pathways, such as cancer, neurodegenerative diseases, and autoimmune diseases.

Conclusion

WIPI2 is a protein that is involved in several cellular processes that are

Protein Name: WD Repeat Domain, Phosphoinositide Interacting 2

Functions: Component of the autophagy machinery that controls the major intracellular degradation process by which cytoplasmic materials are packaged into autophagosomes and delivered to lysosomes for degradation (PubMed:20505359, PubMed:28561066). Involved in an early step of the formation of preautophagosomal structures (PubMed:20505359, PubMed:28561066). Binds and is activated by phosphatidylinositol 3-phosphate (PtdIns3P) forming on membranes of the endoplasmic reticulum upon activation of the upstream ULK1 and PI3 kinases (PubMed:28561066). Mediates ER-isolation membranes contacts by interacting with the ULK1:RB1CC1 complex and PtdIns3P (PubMed:28890335). Once activated, WIPI2 recruits at phagophore assembly sites the ATG12-ATG5-ATG16L1 complex that directly controls the elongation of the nascent autophagosomal membrane (PubMed:20505359, PubMed:28561066)

The "WIPI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WIPI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6 | XPO7 | XPOT | XPR1 | XRCC1 | XRCC2